Skip to main content

Table 4 Phase II study of small molecule antiangiogenic agents in advanced thymic carcinomas

From: The efficacy of small molecule anti-angiogenic drugs in previously treated Thymic carcinoma

Researcher

Year

Study

Drug

Number

mPFS

mOS

ORR

Thomas [11]

2015

Phase II

Sunitinib

25TC

7.2

NA

26.0%

Sato [10]

2020

Phase II

lenvatinib

42TC

9.3

NA

38.0%

Song [23]

2022

Phase II

Apatinib

15TC

6.1

24.0

20.0%

Perrino [15]

2022

Phase II

Regorafenib

8TC

9.2

20.1

0.0%

  1. mPFS median progression-free survival, mOS median overall survival, ORR overall response rate, NA not available
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us